Antihyperglycemic Agents for Diabetes Treatment

Antihyperglycemic agents are essential in managing diabetes, helping to lower blood glucose levels and prevent complications. These agents can be classified into several categories, including biguanides, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. Biguanides, such as metformin, primarily improve insulin sensitivity and reduce hepatic glucose production. Sulfonylureas stimulate insulin secretion from pancreatic beta cells, while thiazolidinediones enhance insulin action in peripheral tissues. DPP-4 inhibitors and GLP-1 receptor agonists promote glucose-dependent insulin secretion and decrease glucagon release. SGLT2 inhibitors, on the other hand, reduce glucose reabsorption in the kidneys, promoting urinary glucose excretion. The choice of antihyperglycemic therapy depends on individual patient factors, including the type of diabetes, comorbidities, and tolerance to medications. A personalized treatment approach is vital for achieving optimal glycemic control and minimizing the risk of complications in diabetic patients.